EGFR and adenocarcinoma: Previous reports have indicated that the incidence of epidermal growth factor receptor (EGFR) mutations is high in Asian populations, reaching 30% in non‐small cell lung cancer (NSCLC) patients and 50% in those with adenocarcinoma.1